MeiraGTx Holdings PLC MGTX:NASDAQ

MeiraGTx Holdings (MGTX) on Tuesday reported positive preliminary data from a phase 1 trial of AAV-hAQP1 to treat grade 2/3 radiation-induced xerostomia, a condition in which the salivary glands in your mouth don't make enough saliva to keep your mouth wet.

Preliminary data showed that the drug candidate can yield clinically meaningful improvements in xerostomia symptoms and disease burden reported in two validated Patient Reported Outcome measures. The drug candidate also appears to be safe and well-tolerated, according to a statement.

The company also reported that one participant with the maximum response evaluable at 12 months has now reached 24 months and the same level of xerostomia symptoms improvement was maintained.

Price: 17.5, Change: +0.45, Percent Change: +2.64